Obstructive sleep apnoea syndrome
RecruitingA study to evaluate the effects of zenagamtide in people with overweight or obesity and obstructive sleep apnoea not treated with positive airway pressure
A study to evaluate the effects of zenagamtide in people with overweight or obesity and obstructive sleep apnoea not treated with positive airway pressure
- Disease:Obstructive sleep apnoea syndrome
- Substances:POLYPEPTIDE CONSISTING OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND AN AMYLIN RECEPTOR AGONIST, CONNECTED BY A LINKER WITH 4 GLYCINE RESIDUES, AND CONNECTED TO A C18 FATTY ACID SIDE CHAIN
Poland- Participants:18–64 years · 65+ years
- Substances:POLYPEPTIDE CONSISTING OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND AN AMYLIN RECEPTOR AGONIST, CONNECTED BY A LINKER WITH 4 GLYCINE RESIDUES, AND CONNECTED TO A C18 FATTY ACID SIDE CHAIN
- Sponsor:Novo Nordisk A/S






